Dihydromyricetin improves liver fat deposition in high-fat diet-induced obese mice

doi:10.5246/jcps.2022.11.070

Abstract

Abstract:

It has been reported that the histone/protein deacetylase SIRT1-AMP-activated protein kinase (SIRT1-AMPK) signaling pathway may play a role in the effects of dihydromyricetin (DHM) on improving triglyceride (TG) accumulation and insulin resistance in liver cells. Therefore, we aimed to further observe the effect of DHM on liver fat deposition in high-fat diet (HFD)-induced obese mice and explore its possible mechanism. C57BL/6J mice were fed with a normal diet (ND) and HFD and were treated with or without low-dose (125 mg/kg) or high-dose (250 mg/kg) DHM for 16 weeks, respectively. During the experiment, body weight was checked every 2 weeks. After 16 weeks, the orbital vein was bled, the animals were sacrificed, and the subscapular, epididymal, and inguinal fat were collected and weighed with an electronic scale. An automatic biochemical analyzer was used to determine the levels of serum triglyceride (TG), serum total cholesterol (TC), serum high-density lipoprotein (HDL), and serum low-density lipoprotein (LDL). The livers were stained with hematoxylin-eosin staining (H&E) and Oil Red O to detect liver fat deposition. A colorimetric method was used to detect liver MDA and SOD contents. Quantitative real-time PCR (qRT-PCR) was used to detect the gene expressions of related indicators, such as interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-α (TNF-α), acetyl-CoA carboxyl acetyl-CoA carboxylase (ACC), sterol regulatory element-binding protein-1c (SREBP-1), fatty acid synthetase (FAS), peroxisome proliferator activation receptor alpha (peroxisome proliferator-activated receptor-alpha, PPARα), palmitoyltransferase 1 (carnitine palmitoyltransferase 1, CPT1), SIRT1, and AMPK. Western blotting analysis was used to detect the protein expression levels of SIRT1, AMPK, SIRT1-AMPK, ACC, SREBP-1, FAS, PPARα, and CPT1. Results showed that compared with the ND group, the weight and body fat of the mice in the HFD group were increased significantly. The levels of TG, TC, and LDL were increased, the level of HDL was decreased, the volume of hepatocytes was increased, the number of lipid droplets, fat deposition, MDA, IL-6, IL-8, TNF-α, SREBP-1c, FAS, ACC1, SIRT1, and AMPK protein levels were significantly increased, and the SOD activity, PPARα, CPT1, SIRT1 mRNA, AMPK mRNA, PPARα, CPT1 levels were significantly decreased. DHM could significantly reverse the changes of the above indexes in HFD mice, while DHM had no significant effect on the above indexes in ND mice. Collectively, our findings revealed that DHM improved liver fat deposition in HFD-induced obese mice, and the mechanism might be related to inhibition of oxidative stress, inflammation, lipid synthesis, and promotion of lipid decomposition.

Key words: Dihydromyricetin, Obese mice, Hepatic fat deposition, Oxidative stress, Inflammation, Lipid synthesis, Lipid breakdown

Supporting:

Huijie Lv, Tuo Xv, Jun Peng, Gang Luo, Jianqin He, Sisi Yang, Tiancheng Zhang, Shuidong Feng, Hongyan Ling. Dihydromyricetin improves liver fat deposition in high-fat diet-induced obese mice[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(11): 824-839.

Figures/Tables 9

References 31

[1]	Zhao, Y.L.; Wang, L.; Xue, B.; Wang, Y.F. Associations between general and central obesity and hypertension among children: the Childhood Obesity Study in China Mega-Cities. Sci. Rep. 2017, 7, 16895.
[2]	Walker, E.; Wolfe, B.M. Editorial comment: obesity in America. Surg. Obes. Relat. Dis. 2017, 13, 1650–1651.
[3]	Africa, J.A.; Newton, K.P.; Schwimmer, J.B. Lifestyle interventions including nutrition, exercise, and supplements for nonalcoholic fatty liver disease in children. Dig. Dis. Sci. 2016, 61, 1375–1386.
[4]	Peixoto, T.C.; Moura, E.G.; de Oliveira, E.; Soares, P.N.; Guarda, D.S.; Bernardino, D.N.; Ai, X.X.; Rodrigues, V.D.S.T.; de Souza, G.R.; da Silva, A.J.R.; Figueiredo, M.S.; Manhães, A.C.; Lisboa, P.C. Cranberry (Vaccinium macrocarpon) extract treatment improves triglyceridemia, liver cholesterol, liver steatosis, oxidative damage and corticosteronemia in rats rendered obese by high fat diet. Eur. J. Nutr. 2018, 57, 1829–1844.
[5]	Daoud, A.; Song, J.; Xiao, F.Y.; Shang, J. B-9-3, a novel β-carboline derivative exhibits anti-cancer activity via induction of apoptosis and inhibition of cell migration in vitro. Eur. J. Pharmacol. 2014, 724, 219–230.
[6]	Veeramani, C.; Alsaif, M.A.; Al-Numair, K.S. Herbacetin, a flaxseed flavonoid, ameliorates high percent dietary fat induced insulin resistance and lipid accumulation through the regulation of hepatic lipid metabolizing and lipid-regulating enzymes. Chem. Biol. Interact. 2018, 288, 49–56.
[7]	Zhang, Q.Y.; Liu, J.; Liu, B.; Xia, J.; Chen, N.P.; Chen, X.F.; Cao, Y.; Zhang, C.; Lu, C.J.; Li, M.Y.; Zhu, R.Z. Dihydromyricetin promotes hepatocellular carcinoma regression via a p53 activation-dependent mechanism. Sci. Rep. 2014, 4, 4628.
[8]	Hou, X.L.; Tong, Q.; Wang, W.Q.; Xiong, W.; Shi, C.Y.; Fang, J.G. Dihydromyricetin protects endothelial cells from hydrogen peroxide-induced oxidative stress damage by regulating mitochondrial pathways. Life Sci. 2015, 130, 38–46.
[9]	Li, C.F.; Zeng, X.L.; Huang, J.; Yang, J.N.; Zhang, Q.Y.; Mi, M.T. Dihydromyricetin improves triglyceride accumulation in HepG2 cells by regulating SIRT1 signaling pathway. J. Third Mil. Med. Univ. 2016, 38, 443–448.
[10]	Liu, T.T.; Zeng, Y.; Tang, K.; Chen, X.M.; Zhang, W.; Xu, X.L. Dihydromyricetin ameliorates atherosclerosis in LDL receptor deficient mice. Atherosclerosis. 2017, 262, 39–50.
[11]	Williams, J.; Ensor, C.; Gardner, S.; Smith, R.; Lodder, R. BSN723T prevents atherosclerosis and weight gain in ApoE knockout mice fed a western diet. WebmedCentral. 2015, 6, WMC005034.
[12]	Hou, X.L.; Tong, Q.; Wang, W.Q.; Shi, C.Y.; Xiong, W.; Chen, J.; Liu, X.; Fang, J.G. Suppression of inflammatory responses by dihydromyricetin, a flavonoid from ampelopsis grossedentata, via inhibiting the activation of NF-κB and MAPK signaling pathways. J. Nat. Prod. 2015, 78, 1689–1696.
[13]	Gong, L.; Guo, S.; Zou, Z. Resveratrol ameliorates metabolic disorders and insulin resistance in high-fat diet-fed mice. Life Sci. 2020, 242, 117212.
[14]	Lee, E.S.; Kwon, M.H.; Hong, M.K. Curcumin analog CUR5–8 ameliorates nonalcoholic fatty liver disease in mice with high-fat diet-induced obesity. Metabolism. 2019, 103, 154015.
[15]	Jia, Q.; Cao, H.; Shen, D.; Li, S.; Yan, L.; Chen, C.; Xing, S.; Dou, F. Quercetin protects against atherosclerosis by regulating the expression of PCSK9, CD36, PPARγ, LXRα and ABCA1. Int. J. Mol. Med. 2019, 44, 893–902.
[16]	Xu, L.; Yu, Y.; Sang, R.; Li, J.; Ge, B.; Zhang, X. Protective effects of taraxasterol against ethanol-induced liver injury by regulating CYP2E1/Nrf2/HO-1 and NF-κB signaling pathways in mice. Oxidative Med. Cell Longev. 2018, 2018, 8284107.
[17]	Cohen, J.C.; Horton, J.D.; Hobbs, H.H. Human fatty liver disease: old questions and new insights. Science. 2011, 332, 1519–1523.
[18]	Zong, H.; Armoni, M.; Harel, C.; Karnieli, E.; Pessin, J.E. Cytochrome P-450 CYP2E1 knockout mice are protected against high-fat diet-induced obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 2012, 302, E532–E539.
[19]	Farrell, G.C.; Larter, C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006, 43, S99–S112.
[20]	Huang, S.Q.; Wan, J.Y.; Du, T.T.; Gong, T.; Zhang, J.; Jiang, X.H. The relationship between the content of 13 amino acids in brain tissue of C57BL/6 mice and the progression of NAFLD disease (English) [J/OL]. J. Chin. Pharm. Sci. 2019, 25, 1–11.
[21]	Younes, R.; Bugianesi, E. Should we undertake surveillance for HCC in patients with NAFLD? J. Hepatol. 2018, 68, 326–334.
[22]	Li, Y.S. Effects of Enshi-ampelopsis grossede on serum lipid and blood rheology and oxygen free radical of hyperlipidemia model rats. J. Hubei Institute Nationalities. 2006, 23, 7–9.
[23]	Wang, J.T.; Jiao, P.; Zhou, Y.; Liu, Q. Protective effect of dihydromyricetin against lipopolysaccharide-induced acute kidney injury in a rat model. Med. Sci. Monit. 2016, 22, 454–459.
[24]	Zhou, Q.C.; Gu, Y.Y.; Lang, H.D.; Wang, X.L.; Chen, K.; Gong, X.H.; Zhou, M.; Ran, L.; Zhu, J.D.; Mi, M.T. Dihydromyricetin prevents obesity-induced slow-twitch-fiber reduction partially via FLCN/FNIP₁/AMPK pathway. Biochim. Biophys. Acta Mol. Basis Dis. 2017, 1863, 1282–1291.
[25]	Schug, T.T.; Li, X. Sirtuin 1 in lipid metabolism and obesity. Ann. Med. 2011, 43, 198–211.
[26]	Ding, R.B.; Bao, J.; Deng, C.X. Emerging roles of SIRT1 in fatty liver diseases. Int. J. Biol. Sci. 2017, 13, 852–867.
[27]	Ponugoti, B.; Kim, D.H.; Xiao, Z.; Smith, Z.; Miao, J.; Zang, M.; Wu, S.Y.; Chiang, C.M.; Veenstra, T.D.; Kemper, J.K. SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J. Biol. Chem. 2010, 285, 33959–33970.
[28]	Kemper, J.K.; Choi, S.E.; Kim, D.H. Sirtuin 1 deacetylase: a key regulator of hepatic lipid metabolism. Vitam. Horm. 2013, 91, 385–404.
[29]	Carling, D. AMPK signalling in health and disease. Curr. Opin. Cell Biol. 2017, 45, 31–37.
[30]	Mottillo, E.P.; Desjardins, E.M.; Crane, J.D.; Smith, B.K.; Green, A.E.; Ducommun, S.; Henriksen, T.I.; Rebalka, I.A.; Razi, A.; Sakamoto, K.; Scheele, C.; Kemp, B.E.; Hawke, T.J.; Ortega, J.; Granneman, J.G.; Steinberg, G.R. Lack of adipocyte AMPK exacerbates insulin resistance and hepatic steatosis through brown and beige adipose tissue function. Cell Metab. 2016, 24, 118–129.
[31]	Fullerton, M.D.; Galic, S.; Marcinko, K.; Sikkema, S.; Pulinilkunnil, T.; Chen, Z.P.; O'Neill, H.M.; Ford, R.J.; Palanivel, R.; O'Brien, M.; Hardie, D.G.; Macaulay, S.L.; Schertzer, J.D.; Dyck, J.R.B.; van Denderen, B.J.; Kemp, B.E.; Steinberg, G.R. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat. Med. 2013, 19, 1649–1654.